Acute promyelocytic leukemia, arsenic, and PML bodies

Journal of Cell Biology

Volumn 198, Issue 1, 2012, Pages 11-21

  de Thé, Hugues ^a,b,c,d   Le Bras, Morgane ^a,b,c   Lallemand Breitenbach, Valérie ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CNRS   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; CHECKPOINT KINASE 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DAXX PROTEIN; HETEROCHROMATIN PROTEIN 1; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; SUMO PROTEIN; ANTINEOPLASTIC AGENT; ONCOPROTEIN; RETINOIC ACID RECEPTOR;

ACETYLATION; APOPTOSIS; ARTICLE; CELL AGING; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CELL STRESS; CHROMOSOME TRANSLOCATION; GROWTH DISORDER; HUMAN; LEUKEMOGENESIS; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUMOYLATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; OXIDATIVE STRESS; RECEPTORS, RETINOIC ACID; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRETINOIN;

EID: 84865074686     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201112044     Document Type: Article

References (134)

1. Ablain, J., and H. de Thé. 2011. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 117:5795-5802. http://dx.doi.org/ 10.1182/blood-2011-02-329367
2. Ablain, J., R. Nasr, A. Bazarbachi, and H. de Thé. 2011. The drug-induced degradation of oncoproteins: an unexpected achilles' heel of cancer cells? Cancer Discov. 1:117-127. http://dx.doi.org/10.1158/2159-8290. CD-11-0087
3. Ascoli, C.A., and G.G. Maul. 1991. Identification of a novel nuclear domain. J. Cell Biol. 112:785-795. http://dx.doi.org/10.1083/jcb.112.5.785
4. Bernardi, R., and P.P. Pandolfi. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016. http://dx.doi.org/10.1038/nrm2277
5. Bernardi, R., P.P. Scaglioni, S. Bergmann, H.F. Horn, K.H. Vousden, and P.P. Pandolfi. 2004. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 6:665-672. http://dx.doi.org/10.1038/ncb1147
6. Bischof, O., O. Kirsh, M. Pearson, K. Itahana, P.G. Pelicci, and A. Dejean. 2002. Deconstructing PML-induced premature senescence. EMBO J. 21:3358-3369. http://dx.doi.org/10.1093/emboj/cdf341
7. Boddy, M.N., K. Howe, L.D. Etkin, E. Solomon, and P.S. Freemont. 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene. 13:971-982.
8. Boisvert, F.M., M.J. Hendzel, and D.P. Bazett-Jones. 2000. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J. Cell Biol. 148:283-292. http://dx.doi.org/10.1083/jcb.148.2.283
9. Brown, D., S. Kogan, E. Lagasse, I. Weissman, M. Alcalay, P.G. Pelicci, S. Atwater, and J.M. Bishop. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:2551-2556. http://dx.doi.org/10.1073/pnas.94.6.2551
10. Butler, J.T., L.L. Hall, K.P. Smith, and J.B. Lawrence. 2009. Changing nuclear landscape and unique PML structures during early epigenetic transitions of human embryonic stem cells. J. Cell. Biochem. 107:609-621. http:// dx.doi.org/10.1002/jcb.22183
11. Chen, Z., N.J. Brand, A. Chen, S.J. Chen, J.H. Tong, Z.Y. Wang, S. Waxman, and A. Zelent. 1993. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12:1161-1167.
12. Cho, G., Y. Lim, and J.A. Golden. 2009. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation. J. Biol. Chem. 284:19592-19600. http://dx.doi.org/10.1074/jbc.M109.010181
13. Chung, I., H. Leonhardt, and K. Rippe. 2011. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation. J. Cell Sci. 124:3603-3618. http://dx.doi.org/ 10.1242/jcs.084681
14. Cicalese, A., G. Bonizzi, C.E. Pasi, M. Faretta, S. Ronzoni, B. Giulini, C. Brisken, S. Minucci, P.P. Di Fiore, and P.G. Pelicci. 2009. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 138:1083-1095. http://dx.doi.org/10.1016/j.cell.2009.06.048
15. Cohen, N., M. Sharma, A. Kentsis, J.M. Perez, S. Strudwick, and K.L. Borden. 2001. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J. 20:4547-4559. http://dx.doi .org/10.1093/emboj/20.16.4547
16. Condemine, W., Y. Takahashi, J. Zhu, F. Puvion-Dutilleul, S. Guegan, A. Janin, and H. de Thé. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66:6192-6198. http://dx.doi .org/10.1158/0008-5472.CAN-05-3792
17. Condemine, W., Y. Takahashi, M. Le Bras, and H. de Thé. 2007. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J. Cell Sci. 120:3219-3227. http://dx.doi .org/10.1242/jcs.007492
18. Daniel, M.-T., M. Koken, O. Romagné, S. Barbey, A. Bazarbachi, M. Stadler, M.-C. Guillemin, L. Degos, C. Chomienne, and H. de Thé. 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 82:1858-1867.
19. Dellaire, G., and D.P. Bazett-Jones. 2004. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays. 26:963-977. http://dx.doi .org/10.1002/bies.20089
20. de Stanchina, E., E. Querido, M. Narita, R.V. Davuluri, P.P. Pandolfi, G. Ferbeyre, and S.W. Lowe. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell. 13:523-535. http://dx.doi.org/ 10.1016/S1097-2765(04)00062-0
21. Desterro, J.M.P., M.S. Rodriguez, and R.T. Hay. 1998. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell. 2:233-239. http://dx.doi.org/10.1016/S1097-2765(00)80133-1
22. de Thé, G., M. Rivière, and W. Bernhard. 1960. Examen au microscope électronique de la tumeur VX2 du lapin domestique dérivée du papillome de Shope. Bull. Cancer. 47:570-584.
23. de Thé, H., and Z. Chen. 2010. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer. 10:775-783. http://dx.doi .org/10.1038/nrc2943
24. de Thé, H., C. Chomienne, M. Lanotte, L. Degos, and A. Dejean. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558-561. http://dx.doi.org/10.1038/347558a0
25. de Thé, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:675-684. http://dx.doi.org/10.1016/0092-8674(91)90113-D
26. Döhner, H., E.H. Estey, S. Amadori, F.R. Appelbaum, T. Büchner, A.K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R.A. Larson, et al. 2010. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453-474. http://dx.doi.org/10.1182/blood-2009-07-235358
27. dos Santos, G.A., R.S. Abreue Lima, C.R. Pestana, A.S. Lima, P.S. Scheucher, C.H. Thomé, H.L. Gimenes-Teixeira, B.A. Santana-Lemos, A.R. Lucena-Araujo, F.P. Rodrigues, et al. 2012. (+)?-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia. 26:451-460. http://dx.doi.org/10.1038/leu.2011.216
28. Draskovic, I., N. Arnoult, V. Steiner, S. Bacchetti, P. Lomonte, and A. Londoño-Vallejo. 2009. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proc. Natl. Acad. Sci. USA. 106:15726-15731. http://dx.doi.org/10.1073/pnas.0907689106
29. Dyck, J.A., G.G. Maul, W.H. Miller Jr., J.D. Chen, A. Kakizuka, and R.M. Evans. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 76:333-343. http:// dx.doi.org/10.1016/0092-8674(94)90340-9
30. Eskiw, C.H., G. Dellaire, J.S. Mymryk, and D.P. Bazett-Jones. 2003. Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J. Cell Sci. 116:4455-4466. http://dx.doi.org/10.1242/jcs.00758
31. Eskiw, C.H., G. Dellaire, and D.P. Bazett-Jones. 2004. Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J. Biol. Chem. 279:9577-9585. http://dx.doi .org/10.1074/jbc.M312580200
32. Estey, E., G. Garcia-Manero, A. Ferrajoli, S. Faderl, S. Verstovsek, D. Jones, and H. Kantarjian. 2006. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 107:3469-3473. http://dx.doi.org/10.1182/blood-2005-10-4006
33. Everett, R.D., J. Murray, A. Orr, and C.M. Preston. 2007. Herpes simplex virus type 1 genomes are associated with ND10 nuclear substructures in quiescently infected human fibroblasts. J. Virol. 81:10991-11004. http:// dx.doi.org/10.1128/JVI.00705-07
34. Ferbeyre, G., E. de Stanchina, E. Querido, N. Baptiste, C. Prives, and S.W. Lowe. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14:2015-2027.
35. Figueroa, M.E., S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P.J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, et al. 2010. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 17:13-27. http://dx.doi .org/10.1016/j.ccr.2009.11.020
36. Ghavamzadeh, A., K. Alimoghaddam, S. Rostami, S.H. Ghaffari, M. Jahani, M. Iravani, S.A. Mousavi, B. Bahar, and M. Jalili. 2011. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 29:2753-2757. http://dx.doi.org/ 10.1200/JCO.2010.32.2107
37. Goto, E., A. Tomita, F. Hayakawa, A. Atsumi, H. Kiyoi, and T. Naoe. 2011. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 118:1600-1609. http://dx.doi .org/10.1182/blood-2011-01-329433
38. Gottifredi, V., and C. Prives. 2001. P53 and PML: new partners in tumor suppression. Trends Cell Biol. 11:184-187. http://dx.doi.org/10.1016/ S0962-8924(01)01983-3
39. Grisolano, J.L., R.L. Wesselschmidt, P.G. Pelicci, and T.J. Ley. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 89:376-387.
40. Gurrieri, C., P. Capodieci, R. Bernardi, P.P. Scaglioni, K. Nafa, L.J. Rush, D.A. Verbel, C. Cordon-Cardo, and P.P. Pandolfi. 2004a. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96:269-279. http://dx.doi.org/10.1093/jnci/djh043
41. Gurrieri, C., K. Nafa, T. Merghoub, R. Bernardi, P. Capodieci, A. Biondi, S. Nimer, D. Douer, C. Cordon-Cardo, R. Gallagher, and P.P. Pandolfi. 2004b. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood. 103:2358-2362. http://dx.doi.org/10 .1182/blood-2003-07-2200
42. Häkli, M., U. Karvonen, O.A. Jänne, and J.J. Palvimo. 2005. SUMO-1 promotes association of SNURF (RNF4) with PML nuclear bodies. Exp. Cell Res. 304:224-233. http://dx.doi.org/10.1016/j.yexcr.2004.10.029
43. Hay, R.T. 2005. SUMO: a history of modification. Mol. Cell. 18:1-12. http:// dx.doi.org/10.1016/j.molcel.2005.03.012
44. Hecker, C.M., M. Rabiller, K. Haglund, P. Bayer, and I. Dikic. 2006. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281:16117-16127. http://dx.doi.org/10.1074/jbc.M512757200
45. Hillestad, L.K. 1957. Acute promyelocytic leukemia. Acta. Med. Scand. 159:189-194. http://dx.doi.org/10.1111/j.0954-6820.1957.tb00124.x
46. Hofmann, T.G., A. Möller, H. Sirma, H. Zentgraf, Y. Taya, W. Dröge, H. Will, and M.L. Schmitz. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:1-10. http://dx.doi.org/10.1038/ncb715
47. Hu, J., Y.F. Liu, C.F. Wu, F. Xu, Z.X. Shen, Y.M. Zhu, J.M. Li, W. Tang, W.L. Zhao, W. Wu, et al. 2009. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 106:3342-3347. http://dx.doi.org/10.1073/pnas.0813280106
48. Insinga, A., S. Monestiroli, S. Ronzoni, R. Carbone, M. Pearson, G. Pruneri, G. Viale, E. Appella, P. Pelicci, and S. Minucci. 2004. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23:1144-1154. http://dx.doi.org/10.1038/sj.emboj.7600109
49. Ishov, A.M., A.G. Sotnikov, D. Negorev, O.V. Vladimirova, N. Neff, T. Kamitani, E.T. Yeh, J.F. Strauss III, and G.G. Maul. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234. http://dx.doi.org/10.1083/jcb.147.2.221
50. Ito, K., R. Bernardi, A. Morotti, S. Matsuoka, G. Saglio, Y. Ikeda, J. Rosenblatt, D.E. Avigan, J. Teruya-Feldstein, and P.P. Pandolfi. 2008. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 453:1072-1078. http://dx.doi.org/10.1038/nature07016
51. Jeanne, M., V. Lallemand-Breitenbach, O. Ferhi, M. Koken, M. Le Bras, S. Duffort, L. Peres, C. Berthier, H. Soilihi, B. Raught, and H. de Thé. 2010. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 18:88-98. http://dx.doi.org/ 10.1016/j.ccr.2010.06.003
52. Jensen, K., C. Shiels, and P.S. Freemont. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20:7223-7233. http://dx.doi.org/10.1038/sj.onc.1204765
53. Jones, L., G. Wei, S. Sevcikova, V. Phan, S. Jain, A. Shieh, J.C. Wong, M. Li, J. Dubansky, M.L. Maunakea, et al. 2010. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J. Exp. Med. 207:2581-2594. http://dx.doi.org/10.1084/jem.20091071
54. Kamei, H. 1997. Cystine starvation induces reversible large-body formation from nuclear bodies in T24 cells. Exp. Cell Res. 237:207-216. http://dx.doi .org/10.1006/excr.1997.3790
55. Kawata, K., H. Yokoo, R. Shimazaki, and S. Okabe. 2007. Classification of heavy-metal toxicity by human DNA microarray analysis. Environ. Sci. Technol. 41:3769-3774. http://dx.doi.org/10.1021/es062717d
56. Kogan, S.C., S.H. Hong, D.B. Shultz, M.L. Privalsky, and J.M. Bishop. 2000. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood. 95:1541-1550.
57. Koken, M.H.M., F. Puvion-Dutilleul, M.C. Guillemin, A. Viron, G. Linares-Cruz, N. Stuurman, L. de Jong, C. Szostecki, F. Calvo, C. Chomienne, et al. 1994. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13:1073-1083.
58. Koken, M.H.M., G. Linares-Cruz, F. Quignon, A. Viron, M.K. Chelbi-Alix, J. Sobczak-Thépot, L. Juhlin, L. Degos, F. Calvo, and H. de Thé. 1995. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene. 10:1315-1324.
59. Lallemand-Breitenbach, V., and H. de Thé. 2010. PML nuclear bodies. Cold Spring Harb. Perspect. Biol. 2:a000661. http://dx.doi.org/10.1101/cshperspect. a000661
60. Lallemand-Breitenbach, V., M.-C. Guillemin, A. Janin, M.-T. Daniel, L. Degos, S.C. Kogan, J.M. Bishop, and H. de Thé. 1999. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1043-1052. http://dx.doi.org/ 10.1084/jem.189.7.1043
61. Lallemand-Breitenbach, V., J. Zhu, F. Puvion, M. Koken, N. Honoré, A. Doubeikovsky, E. Duprez, P.P. Pandolfi, E. Puvion, P. Freemont, and H. de Thé. 2001. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor ? degradation. J. Exp. Med. 193:1361-1371. http://dx.doi.org/10.1084/jem.193.12.1361
62. Lallemand-Breitenbach, V., J. Zhu, S. Kogan, Z. Chen, and H. de Thé. 2005. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat. Rev. Cancer. 5:821-827. http://dx.doi .org/10.1038/nrc1719
63. Lallemand-Breitenbach, V., M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou, J. Zhu, B. Raught, and H. de Thé. 2008. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ ubiquitin-mediated pathway. Nat. Cell Biol. 10:547-555. http://dx.doi .org/10.1038/ncb1717
64. Lallemand-Breitenbach, V., J. Zhu, Z. Chen, and H. de Thé. 2012. Curing APL through PML/RARA degradation by As2O3. Trends Mol. Med. 18:36-42. http://dx.doi.org/10.1016/j.molmed.2011.10.001
65. LaMorte, V.J., J.A. Dyck, R.L. Ochs, and R.M. Evans. 1998. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. USA. 95:4991-4996. http://dx.doi .org/10.1073/pnas.95.9.4991
66. Lang, M., T. Jegou, I. Chung, K. Richter, S. Münch, A. Udvarhelyi, C. Cremer, P. Hemmerich, J. Engelhardt, S.W. Hell, and K. Rippe. 2010. Threedimensional organization of promyelocytic leukemia nuclear bodies. J. Cell Sci. 123:392-400. http://dx.doi.org/10.1242/jcs.053496
67. Lehembre, F., S. Müller, P.P. Pandolfi, and A. Dejean. 2001. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene. 20:1-9. http://dx.doi.org/10.1038/sj.onc.1204063
68. Ley, T.J., E.R. Mardis, L. Ding, B. Fulton, M.D. McLellan, K. Chen, D. Dooling, B.H. Dunford-Shore, S. McGrath, M. Hickenbotham, et al. 2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 456:66-72. http://dx.doi.org/10.1038/ nature07485
69. Licht, J.D., C. Chomienne, A. Goy, A. Chen, A.A. Scott, D.R. Head, J.L. Michaux, Y. Wu, A. DeBlasio, W.H. Miller Jr., et al. 1995. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 85:1083-1094.
70. Lin, D.Y., Y.S. Huang, J.C. Jeng, H.Y. Kuo, C.C. Chang, T.T. Chao, C.C. Ho, Y.C. Chen, T.P. Lin, H.I. Fang, et al. 2006. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell. 24:341-354. http:// dx.doi.org/10.1016/j.molcel.2006.10.019
71. Liu, Y., S.E. Elf, Y. Miyata, G. Sashida, Y. Liu, G. Huang, S. Di Giandomenico, J.M. Lee, A. Deblasio, S. Menendez, et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 4:37-48. http://dx.doi .org/10.1016/j.stem.2008.11.006
72. Look, A.T. 1997. Oncogenic transcription factors in the human acute leukemias. Science. 278:1059-1064. http://dx.doi.org/10.1126/science.278.5340.1059
73. Martens, J.H., A.B. Brinkman, F. Simmer, K.J. Francoijs, A. Nebbioso, F. Ferrara, L. Altucci, and H.G. Stunnenberg. 2010. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 17:173-185. http://dx.doi.org/10.1016/j.ccr.2009.12.042
74. Matera, A.G. 1999. Nuclear bodies: multifaceted subdomains of the interchromatin space. Trends Cell Biol. 9:302-309. http://dx.doi.org/10.1016/S0962-8924(99)01606-2
75. Mathews, V., B. George, E. Chendamarai, K.M. Lakshmi, S. Desire, P. Balasubramanian, A. Viswabandya, R. Thirugnanam, A. Abraham, R.V. Shaji, et al. 2010. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J. Clin. Oncol. 28:3866-3871. http://dx.doi.org/10.1200/JCO .2010.28.5031
76. Matsushita, H., P.P. Scaglioni, M. Bhaumik, E.M. Rego, L.F. Cai, S.M. Majid, H. Miyachi, A. Kakizuka, W.H. Miller Jr., and P.P. Pandolfi. 2006. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR? blockade in the pathogenesis of acute promyelocytic leukemia. J. Exp. Med. 203:821-828. http://dx.doi.org/10.1084/ jem.20050616
77. Mattsson, K., K. Pokrovskaja, C. Kiss, G. Klein, and L. Szekely. 2001. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasomedependent protein degradation. Proc. Natl. Acad. Sci. USA. 98:1012-1017. http://dx.doi.org/10.1073/pnas.031566998
78. Melnick, A., and J.D. Licht. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 93:3167-3215.
79. Meulmeester, E., M. Kunze, H.H. Hsiao, H. Urlaub, and F. Melchior. 2008. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol. Cell. 30:610-619. http://dx.doi .org/10.1016/j.molcel.2008.03.021
80. Müller, S., M.J. Matunis, and A. Dejean. 1998. Conjugation with the ubiquitinrelated modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61-70. http://dx.doi.org/10.1093/emboj/17.1.61
81. Muromoto, R., M. Ishida, K. Sugiyama, Y. Sekine, K. Oritani, K. Shimoda, and T. Matsuda. 2006. Sumoylation of Daxx regulates IFN-induced growth suppression of B lymphocytes and the hormone receptor-mediated transactivation. J. Immunol. 177:1160-1170.
82. Nardella, C., A. Lunardi, A. Patnaik, L.C. Cantley, and P.P. Pandolfi. 2011. The APL paradigm and the " co-clinical trial" project. Cancer Discov. 1:108-116. http://dx.doi.org/10.1158/2159-8290.CD-11-0061
83. Nasr, R., M.C. Guillemin, O. Ferhi, H. Soilihi, L. Peres, C. Berthier, P. Rousselot, M. Robledo-Sarmiento, V. Lallemand-Breitenbach, B. Gourmel, et al. 2008. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 14:1333-1342. http:// dx.doi.org/10.1038/nm.1891
84. Negorev, D.G., O.V. Vladimirova, and G.G. Maul. 2009. Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. J. Virol. 83:5168-5180. http://dx.doi .org/10.1128/JVI.02083-08
85. Negorev, D.G., O.V. Vladimirova, A.V. Kossenkov, E.V. Nikonova, R.M. Demarest, A.J. Capobianco, M.K. Showe, F.J. Rauscher III, L.C. Showe, and G.G. Maul. 2010. Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program. Cancer Res. 70:9991-10001. http://dx.doi.org/10.1158/0008-5472.CAN-10-1483
86. Occhionorelli, M., F. Santoro, I. Pallavicini, A. Gruszka, S. Moretti, D. Bossi, A. Viale, D. Shing, S. Ronzoni, I. Muradore, et al. 2011. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. Leukemia. 25:814-820. http:// dx.doi.org/10.1038/leu.2011.18
87. Pearson, M., R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli, S. Saito, Y. Higashimoto, E. Appella, S. Minucci, P.P. Pandolfi, and P.G. Pelicci. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:207-210. http://dx.doi.org/10.1038/35018127
88. Pekovic, V., I. Gibbs-Seymour, E. Markiewicz, F. Alzoghaibi, A.M. Benham, R. Edwards, M. Wenhert, T. von Zglinicki, and C.J. Hutchison. 2011. Conserved cysteine residues in the mammalian lamin A tail are essential for cellular responses to ROS generation. Aging Cell. 10:1067-1079. http://dx.doi.org/10.1111/j.1474-9726.2011.00750.x
89. Piazza, F., C. Gurrieri, and P.P. Pandolfi. 2001. The theory of APL. Oncogene. 20:7216-7222. http://dx.doi.org/10.1038/sj.onc.1204855
90. Potts, P.R., and H. Yu. 2007. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat. Struct. Mol. Biol. 14:581-590. http://dx.doi.org/10.1038/nsmb1259
91. Quignon, F., Z. Chen, and H. de Thé. 1997. Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia. Biochim. Biophys. Acta. 1333:M53-M61.
92. Quignon, F., F. De Bels, M. Koken, J. Feunteun, J.-C. Ameisen, and H. de Thé. 1998. PML induces a novel caspase-independent death process. Nat. Genet. 20:259-265. http://dx.doi.org/10.1038/3068
93. Raelson, J.V., C. Nervi, A. Rosenauer, L. Benedetti, Y. Monczak, M. Pearson, P.G. Pelicci, and W.H. Miller Jr. 1996. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 88:2826-2832.
94. Regad, T., C. Bellodi, P. Nicotera, and P. Salomoni. 2009. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat. Neurosci. 12:132-140. http://dx.doi.org/10.1038/nn.2251
95. Rego, E.M., L.Z. He, R.P. Warrell Jr., Z.G. Wang, and P.P. Pandolfi. 2000. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. USA. 97:10173-10178. http://dx.doi .org/10.1073/pnas.180290497
96. Rego, E.M., Z.G. Wang, D. Peruzzi, L.Z. He, C. Cordon-Cardo, and P.P. Pandolfi. 2001. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193:521-529. http://dx.doi.org/10.1084/jem.193.4.521
97. Rowley, J.D., H.M. Golomb, and C. Dougherty. 1977. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 309:549-550. http://dx.doi.org/10.1016/S0140-6736(77)91415-5
98. Sawyers, C.L. 2008. The cancer biomarker problem. Nature. 452:548-552. http://dx.doi.org/10.1038/nature06913
99. Scaglioni, P.P., T.M. Yung, L.F. Cai, H. Erdjument-Bromage, A.J. Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst, and P.P. Pandolfi. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 126:269-283. http://dx.doi.org/10.1016/j.cell.2006.05.041
100. Shen, T.H., H.K. Lin, P.P. Scaglioni, T.M. Yung, and P.P. Pandolfi. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell. 24:331-339. http://dx.doi.org/10.1016/j.molcel.2006.09.013
101. Shen, Z.X., Z.Z. Shi, J. Fang, B.W. Gu, J.M. Li, Y.M. Zhu, J.Y. Shi, P.Z. Zheng, H. Yan, Y.F. Liu, et al. 2004. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 101:5328-5335. http://dx.doi.org/10.1073/pnas.0400053101
102. Shiels, C., S.A. Islam, R. Vatcheva, P. Sasieni, M.J. Sternberg, P.S. Freemont, and D. Sheer. 2001. PML bodies associate specifically with the MHC gene cluster in interphase nuclei. J. Cell Sci. 114:3705-3716.
103. Shtutman, M., J. Zhurinsky, M. Oren, E. Levina, and A. Ben-Ze'ev. 2002. PML is a target gene of beta-catenin and plakoglobin, and coactivates beta-cateninmediated transcription. Cancer Res. 62:5947-5954.
104. Sohal, J., V.T. Phan, P.V. Chan, E.M. Davis, B. Patel, L.M. Kelly, T.J. Abrams, A.M. O'Farrell, D.G. Gilliland, M.M. Le Beau, and S.C. Kogan. 2003. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 101:3188-3197. http://dx.doi.org/10.1182/blood-2002-06-1800
105. Stadler, M., M.K. Chelbi-Alix, M.H.M. Koken, L. Venturini, C. Lee, A. Saïb, F. Quignon, L. Pelicano, M.-C. Guillemin, C. Schindler, and H. de Thé. 1995. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene. 11:2565-2573.
106. Stehmeier, P., and S. Muller. 2009. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol. Cell. 33:400-409. http://dx.doi.org/10.1016/j.molcel.2009.01.013
107. Sternsdorf, T., V.T. Phan, M.L. Maunakea, C.B. Ocampo, J. Sohal, A. Silletto, F. Galimi, M.M. Le Beau, R.M. Evans, and S.C. Kogan. 2006. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell. 9:81-94. http://dx.doi.org/10.1016/j.ccr.2005.12.030
108. Stuurman, N., A. de Graaf, A. Floore, A. Josso, B. Humbel, L. de Jong, and R. van Driel. 1992a. A monoclonal antibody recognizing nuclear matrixassociated nuclear bodies. J. Cell Sci. 101:773-784.
109. Stuurman, N., A. Floore, A. Colen, L. de Jong, and R. van Driel. 1992b. Stabilization of the nuclear matrix by disulfide bridges: identification of matrix polypeptides that form disulfides. Exp. Cell Res. 200:285-294. http://dx.doi.org/10.1016/0014-4827(92)90174-7
110. Sung, K.S., Y.A. Lee, E.T. Kim, S.R. Lee, J.H. Ahn, and C.Y. Choi. 2011. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53. Exp. Cell Res. 317:1060-1070. http://dx.doi .org/10.1016/j.yexcr.2010.12.016
111. Szostecki, C., H.H. Guldner, H.J. Netter, and H. Will. 1990. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145:4338-4347.
112. Tallman, M.S., and J.K. Altman. 2009. How I treat acute promyelocytic leukemia. Blood. 114:5126-5135. http://dx.doi.org/10.1182/blood-2009-07-216457
113. Tallman, M.S., and H.C. Kwaan. 1992. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 79:543-553.
114. Tatham, M.H., M.C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E.G. Jaffray, J.J. Palvimo, and R.T. Hay. 2008. RNF4 is a poly-SUMOspecific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538-546. http://dx.doi.org/10.1038/ncb1716
115. Tsukamoto, T., N. Hashiguchi, S.M. Janicki, T. Tumbar, A.S. Belmont, and D.L. Spector. 2000. Visualization of gene activity in living cells. Nat. Cell Biol. 2:871-878. http://dx.doi.org/10.1038/35046510
116. Vernier, M., V. Bourdeau, M.F. Gaumont-Leclerc, O. Moiseeva, V. Bégin, F. Saad, A.M. Mes-Masson, and G. Ferbeyre. 2011. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev. 25:41-50. http://dx.doi .org/10.1101/gad.1975111
117. Wang, H., X.Y. Chen, B.S. Wang, Z.X. Rong, H. Qi, and H.Z. Chen. 2011. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk. Res. 35:1170-1177. http://dx.doi.org/10.1016/j.leukres.2011.06.002
118. Wang, Z.Y., and Z. Chen. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 111:2505-2515. http://dx.doi.org/10.1182/blood-2007-07-102798
119. Warrell, R.P., Jr., H. de Thé, Z.Y. Wang, and L. Degos. 1993. Acute promyelocytic leukemia. N. Engl. J. Med. 329:177-189. http://dx.doi.org/ 10.1056/NEJM199307153290307
120. Wartman, L.D., D.E. Larson, Z. Xiang, L. Ding, K. Chen, L. Lin, P. Cahan, J.M. Klco, J.S. Welch, C. Li, et al. 2011. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J. Clin. Invest. 121:1445-1455. http://dx.doi.org/ 10.1172/JCI45284
121. Weidtkamp-Peters, S., T. Lenser, D. Negorev, N. Gerstner, T.G. Hofmann, G. Schwanitz, C. Hoischen, G. Maul, P. Dittrich, and P. Hemmerich. 2008. Dynamics of component exchange at PML nuclear bodies. J. Cell Sci. 121:2731-2743. http://dx.doi.org/10.1242/jcs.031922
122. Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond, and A. Dejean. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell. 76:345-356. http://dx.doi.org/10.1016/0092-8674(94)90341-7
123. Welch JS, W. Yuan, and T.J. Ley. 2008. Expression of PML-RAR alpha by the murine PML locus leads to myeloid self-renewal, clonal expansion and morphologic promyelocytic leukemia. Blood. 112:344-345.
124. Yang, S., C. Kuo, J.E. Bisi, and M.K. Kim. 2002. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4:865-870. http://dx.doi.org/10.1038/ncb869
125. Ye, X., B. Zerlanko, R. Zhang, N. Somaiah, M. Lipinski, P. Salomoni, and P.D. Adams. 2007. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol. Cell. Biol. 27:2452-2465. http://dx.doi .org/10.1128/MCB.01592-06
126. Zhang, R., M.V. Poustovoitov, X. Ye, H.A. Santos, W. Chen, S.M. Daganzo, J.P. Erzberger, I.G. Serebriiskii, A.A. Canutescu, R.L. Dunbrack, et al. 2005. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev. Cell. 8:19-30. http://dx.doi.org/10.1016/j.devcel.2004.10.019
127. Zhang, X.W., X.J. Yan, Z.R. Zhou, F.F. Yang, Z.Y. Wu, H.B. Sun, W.X. Liang, A.X. Song, V. Lallemand-Breitenbach, M. Jeanne, et al. 2010. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240-243. http://dx.doi.org/101126/science.1183424
128. Zhao, Z., J. Zuber, E. Diaz-Flores, L. Lintault, S.C. Kogan, K. Shannon, and S.W. Lowe. 2010. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24:1389-1402. http://dx.doi .org/10.1101/gad.1940710
129. Zheng, H., H. Ying, H. Yan, A.C. Kimmelman, D.J. Hiller, A.J. Chen, S.R. Perry, G. Tonon, G.C. Chu, Z. Ding, et al. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 455:1129-1133. http://dx.doi.org/10.1038/nature07443
130. Zhu, J., M.H.M. Koken, F. Quignon, M.K. Chelbi-Alix, L. Degos, Z.Y. Wang, Z. Chen, and H. de Thé. 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:3978-3983. http://dx.doi .org/10.1073/pnas.94.8.3978
131. Zhu, J., M. Gianni, E. Kopf, N. Honoré, M. Chelbi-Alix, M. Koken, F. Quignon, C. Rochette-Egly, and H. de Thé. 1999. Retinoic acid induces proteasomedependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc. Natl. Acad. Sci. USA. 96:14807-14812. http://dx.doi.org/10.1073/pnas.96.26.14807
132. Zhu, J., V. Lallemand-Breitenbach, and H. de Thé. 2001. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 20:7257-7265. http://dx.doi.org/10.1038/sj.onc.1204852
133. Zhu, J., Z. Chen, V. Lallemand-Breitenbach, and H. de Thé. 2002. How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer. 2:705-713. http://dx.doi.org/10.1038/nrc887
134. Zhu, J., J. Zhou, L. Peres, F. Riaucoux, N. Honoré, S. Kogan, and H. de Thé. 2005. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 7:143-153. http://dx.doi.org/10.1016/j.ccr.2005.01.005